These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16818523)

  • 1. Preclinical pharmacokinetics and metabolism of a novel diaryl pyrazole resorcinol series of heat shock protein 90 inhibitors.
    Smith NF; Hayes A; James K; Nutley BP; McDonald E; Henley A; Dymock B; Drysdale MJ; Raynaud FI; Workman P
    Mol Cancer Ther; 2006 Jun; 5(6):1628-37. PubMed ID: 16818523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors.
    Sharp SY; Boxall K; Rowlands M; Prodromou C; Roe SM; Maloney A; Powers M; Clarke PA; Box G; Sanderson S; Patterson L; Matthews TP; Cheung KM; Ball K; Hayes A; Raynaud F; Marais R; Pearl L; Eccles S; Aherne W; McDonald E; Workman P
    Cancer Res; 2007 Mar; 67(5):2206-16. PubMed ID: 17332351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice.
    Smith NF; Hayes A; Nutley BP; Raynaud FI; Workman P
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):475-86. PubMed ID: 15526201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Amino derivatives of the Hsp90 inhibitor CCT018159.
    Barril X; Beswick MC; Collier A; Drysdale MJ; Dymock BW; Fink A; Grant K; Howes R; Jordan AM; Massey A; Surgenor A; Wayne J; Workman P; Wright L
    Bioorg Med Chem Lett; 2006 May; 16(9):2543-8. PubMed ID: 16480864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors.
    Cheung KM; Matthews TP; James K; Rowlands MG; Boxall KJ; Sharp SY; Maloney A; Roe SM; Prodromou C; Pearl LH; Aherne GW; McDonald E; Workman P
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3338-43. PubMed ID: 15955698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues.
    Sharp SY; Prodromou C; Boxall K; Powers MV; Holmes JL; Box G; Matthews TP; Cheung KM; Kalusa A; James K; Hayes A; Hardcastle A; Dymock B; Brough PA; Barril X; Cansfield JE; Wright L; Surgenor A; Foloppe N; Hubbard RE; Aherne W; Pearl L; Jones K; McDonald E; Raynaud F; Eccles S; Drysdale M; Workman P
    Mol Cancer Ther; 2007 Apr; 6(4):1198-211. PubMed ID: 17431102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
    Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
    Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro metabolism of BIIB021, an inhibitor of heat shock protein 90, in liver microsomes and hepatocytes of rats, dogs, and humans and recombinant human cytochrome P450 isoforms.
    Xu L; Woodward C; Khan S; Prakash C
    Drug Metab Dispos; 2012 Apr; 40(4):680-93. PubMed ID: 22217465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors.
    van der Kraan AG; Chai RC; Singh PP; Lang BJ; Xu J; Gillespie MT; Price JT; Quinn JM
    Biochem J; 2013 Apr; 451(2):235-44. PubMed ID: 23379601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Progress in the study of heat shock protein 90 inhibitors].
    Luo HM; Sun W; Yin JY; Yang XH
    Yao Xue Xue Bao; 2010 Jul; 45(7):813-20. PubMed ID: 20931776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor.
    Pasha MK; Jayaraman R; Reddy VP; Yeo P; Goh E; Williams A; Goh KC; Kantharaj E
    Drug Metab Lett; 2012 Mar; 6(1):33-42. PubMed ID: 22372550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man.
    Allan G; Davis J; Dickins M; Gardner I; Jenkins T; Jones H; Webster R; Westgate H
    Xenobiotica; 2008 Jun; 38(6):620-40. PubMed ID: 18570162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor alpha agonist in preclinical species and human.
    Frederick KS; Maurer TS; Kalgutkar AS; Royer LJ; Francone OL; Winter SM; Terra SG; Chen D; Gao X
    Xenobiotica; 2009 Oct; 39(10):766-81. PubMed ID: 19622022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical and clinical pharmacokinetics of PF-02413873, a nonsteroidal progesterone receptor antagonist.
    Bungay PJ; Tweedy S; Howe DC; Gibson KR; Jones HM; Mount NM
    Drug Metab Dispos; 2011 Aug; 39(8):1396-405. PubMed ID: 21543556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Pyrazolo[1,5-a]pyrimidines as Translocator Protein 18 kDa (TSPO) Ligands: Synthesis, in Vitro Biological Evaluation, [(18)F]-Labeling, and in Vivo Neuroinflammation PET Images.
    Damont A; Médran-Navarrete V; Cacheux F; Kuhnast B; Pottier G; Bernards N; Marguet F; Puech F; Boisgard R; Dollé F
    J Med Chem; 2015 Sep; 58(18):7449-64. PubMed ID: 26280386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species.
    Venkatesh PR; Goh E; Zeng P; New LS; Xin L; Pasha MK; Sangthongpitag K; Yeo P; Kantharaj E
    Biol Pharm Bull; 2007 May; 30(5):1021-4. PubMed ID: 17473456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics of a novel HIV-1 attachment inhibitor BMS-378806 and prediction of its human pharmacokinetics.
    Yang Z; Zadjura L; D'Arienzo C; Marino A; Santone K; Klunk L; Greene D; Lin PF; Colonno R; Wang T; Meanwell N; Hansel S
    Biopharm Drug Dispos; 2005 Dec; 26(9):387-402. PubMed ID: 16142720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.